Cartesian Therapeutics (RNAC) CFO sells shares to cover tax withholding

Rhea-AI Filing Summary

Cartesian Therapeutics, Inc. reported an insider transaction by its Chief Financial Officer, Blaine Davis. On 01/06/2026, Davis sold 10,591 shares of the company’s common stock at an average price of $6.8197 per share. According to the disclosure, these shares were sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees, indicating a tax-related sale rather than a discretionary open-market reduction in holdings. Following this transaction, Davis beneficially owned 121,220 shares of Cartesian Therapeutics common stock directly.

Insider Trade Summary

Net Seller: 10,591 shares ($72,227)

Net Sell 1 txn

Insider Davis Blaine

Role Chief Financial Officer

Sold 10,591 shs ($72K)

Type	Security	Shares	Price	Value
Sale	Common Stock	10,591	$6.8197	$72K

Holdings After Transaction: Common Stock — 121,220 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Davis Blaine

(Last) (First) (Middle)

C/O CARTESIAN THERAPEUTICS, INC.

7495 NEW HORIZON WAY

(Street)

FREDERICK MD 21703

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Cartesian Therapeutics, Inc. [ RNAC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/06/2026		S		10,591	D	$6.8197(1)	121,220	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees.

Remarks:

	/s/ Matthew Bartholomae, Attorney-in-Fact for Blaine Davis	01/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Cartesian Therapeutics (RNAC) disclose in this Form 4?

The filing reports that Chief Financial Officer Blaine Davis sold 10,591 shares of Cartesian Therapeutics common stock on 01/06/2026.

At what price were the Cartesian Therapeutics (RNAC) shares sold by the CFO?

The 10,591 shares of Cartesian Therapeutics common stock were sold at an average price of $6.8197 per share.

Why did the Cartesian Therapeutics CFO sell 10,591 shares according to the Form 4?

The Form 4 states the shares were sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees.

How many Cartesian Therapeutics (RNAC) shares does the CFO own after this transaction?

After the reported sale, Chief Financial Officer Blaine Davis beneficially owned 121,220 shares of Cartesian Therapeutics common stock directly.

Is the Cartesian Therapeutics CFO’s share sale a direct or indirect holding transaction?

The Form 4 labels the CFO’s ownership as Direct (D), meaning the reported holdings and transaction are in his direct name rather than through an intermediary entity.

What type of security was involved in the Cartesian Therapeutics insider transaction?

The transaction involved shares of Cartesian Therapeutics’ Common Stock, reported as a non-derivative security in Table I of the Form 4.